Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens

K. W. Annie Bang, Edwin R. Speck, Victor S. Blanchette, John Freedman, and John W. Semple

Recipients' IgG immunity against leukoreduced donor platelets is dependent on indirect T-cell allorecognition and is suppressed in vivo by inhibitors (aminoguanidine, AMG) of inducible nitric oxide synthase (iNOS). To examine recipient processing pathways of donor platelet antigens, enriched macrophages (antigen-presenting cells [APC]) from BALB/c (H-2^d) mice were pulsed with allogeneic C57BL/6 (H-2^b) platelets and transfused weekly into naive BALB/c mice. Platelet-pulsed APC stimulated IgG antidonor antibody production in 45% of recipients by the second transfusion and in 100% by the sixth transfusion; this response was enhanced by pulsing in the presence of interferon-γ. By the sixth transfusion, high-titer IgG1 (mean titer 4990) and IgG2a (1933) isotypes specific for donor major histocompatibility complex (MHC) class I antigens were detected. Platelet pulsing in the presence of AMG or chloroquine significantly inhibited the ability of APC to stimulate IgG alloantibodies; only 50% (P < .005) and 20% (P < .0001) of recipients, respectively, produced antibodies by the sixth transfusion. AMG inhibition was reversed by the addition of L-arginine, the substrate for iNOS. In contrast, pulsing in the presence of chloroquine, the proteasome inhibitory peptide MG115, or Brefeldin A enhanced APC immunity (70-100% of recipients antibody positive by the second transfusion [P < .05]); these agents allowed the pulsed APC to stimulate IgG2a but inhibited IgG1 production and this correlated with a reduction in serum interleukin (IL)-4 levels. The results suggest that for donor platelet antigens to stimulate IgG alloantibodies, recipient APC use the essential generation of nitric oxide and a noncytotoxic, pH-independent processing pathway, which can be exploited as an effective immunotherapy target to further inhibit alloimmunization against leukoreduced platelets. (Blood. 2000;95:1735-1742)

© 2000 by The American Society of Hematology

Introduction

Production of IgG antibodies is critically dependent on T-cell recognition and activation. T cells recognize protein antigens, which are degraded or processed and combined with molecules encoded by the major histocompatibility complex (MHC). Antigen processing is critical for generating protein determinants that can be loaded and bound within the antigen-binding grooves of either MHC class I or II molecules. The spectrum of antigen processing ranges from the simple unfolding of conformational determinants to the proteolytic exposure of primary structure by pH-dependent enzymes (eg, cathepsins). Exogenous proteins (eg, bacterial glycoproteins) are generally processed by antigen-presenting cells (APC) via endosomal compartments and are shunted to intracellular compartments rich in MHC class II molecules. This pathway is necessary for the activation of CD4+ T-helper cells and for eventual IgG antibody production. Endogenous antigens (eg, virally derived proteins), on the other hand, are processed by large molecular weight proteasomes within the APC cytosol and are subsequently transported to the luminal surface of the endoplasmic reticulum for loading onto MHC class I molecules. This pathway is responsible for the stimulation of CD8+ cytotoxic T cells (CTL). Experimentally, the major distinction between these pathways has been that exogenous antigen processing is generally susceptible to pH-raising lysosomal agents such as chloroquine and NH_4Cl, whereas the endogenous or nonendosomal pathway is not. Understanding antigen-processing pathways of clinically relevant protein antigens such as platelet alloantigens may be fundamental to developing efficacious antigen-specific therapies for alloimmunization.

Two recipient T-cell recognition mechanisms have been shown to initiate alloimmunity. The direct pathway occurs when recipient T-helper cells directly interact with MHC class II molecules on donor APC, whereas the indirect pathway is analogous to the normal immune response. Indirect recognition occurs when allogeneic non-APC are administered to a recipient and involves the processing and presentation of allelic donor antigens (eg, MHC class I molecules) by recipient APC to recipient T-helper cells. The indirect pathway of allorecognition has been implicated in rejection responses in various transplantation models of cardiac, kidney, and skin grafts. Within the context of indirect allorecognition, interactions between donor antigen and self-APC are critical to T-cell activation and subsequent antibody formation. In 1995, 2 laboratories using different animal models (murine versus rat) of platelet immunity suggested that allogeneic platelets stimulated IgG antidonor immunity via indirect recognition. We demonstrated that the indirect alloimmunity against platelets was dependent on the activation of inducible nitric oxide synthase (iNOS) within recipient macrophages. These results suggested that recipient macrophages may mediate platelet alloimmunity via their known roles as a phagocyte and APC. However, the mechanisms by which donor platelets are engulfed, processed,
and presented to the recipient’s immune system to stimulate IgG antidonor immunity remain unknown. To study the antigen-processing pathways of allogeic platelet antigens, adherent APC from recipient mice were pulsed with donor platelets in the presence of various metabolic inhibitors and then examined for their ability to stimulate alloantibodies in naive recipient mice. The results show that recipient APC use unique intracellular pathway(s) to process allogeic platelet MHC antigens for the stimulation of recipient immunity and suggest that manipulating these pathways may be an effective form of immunotherapy.

**Materials and methods**

**Animals and cell lines**

Inbred female BALB/c (H-2d) mice, 8 to 12 weeks of age, were used as the source of APC; female C57BL/6 (H-2b) mice, 6 to 12 weeks of age, were used as platelet donors; the mice were purchased from Harlan-Sprague Dawley (Indianapolis, IN). EL-4 (H-2b) C57BL/6 thymoma, P815 (H-2b) DBA mastocytoma, and RT 1.1 (H-2b) CBA lymphoma cell lines were used for serologic typing of the recipient sera. All cell lines and cell culture assays were maintained in RPMI-1640 with 5% fetal calf serum (FCS), 100 µg/mL penicillin/streptomycin/fungizone, 100 M j g/mL L-glutamine, and 5 x 10^-5 mol/L 2-mercaptoethanol (cRPMI).

**Chemicals**

Aminoguanidine (AMG), L-arginine (L-arg), colchicine, chloroquine, NH4 Cl, brefeldin A, and the proteasome inhibitor peptide carbobenzoxy-L-leucyl-L-norvalinal (MG115) were obtained from the Sigma Chemical Co. (St. Louis, MO). Recombinant murine interferon (IFN)-γ (100 U/mL final) or the chemical inhibitors (0.5 or 1.0 mM AMG; 1 µg/mL colchicine; 0.1 mM chloroquine, 50 mM NH4 Cl, 1 µg/mL Brefeldin A, or 5 µM MG115, Table 2) were added to the platelet-pulsing step.

**Antibodies**

Fluorescein isothiocyanate (FITC)- and phycoerythrin (PE)-conjugated antibodies against CD45, CD4, CD8, CD61, F4/80, H-2 I-A d /I-E d , H-2D d , and B220 were obtained from Cedarlane Laboratories (Hornby, Ontario, Canada) and used to phenotype the adherent APC populations.

**Platelet preparation**

C57BL/6 donor mice were bled and leukoreduced platelets were prepared as previously described. Briefly, mice were bled via the tail vein into EDTA-microvets (Sarstedt, St. Laurent, Canada), the blood was pooled and centrifuged at 220 g, and the platelet-rich plasma (PRP) collected; care was taken not to disturb or aspirate the buffy coat. The platelets were washed 3 times in 1% EDTA saline and adjusted to a concentration of 1.9 x 10^11 platelets/mL (stock solution, this concentration approximates a 300-mL platelet product). At these levels, allogeneic WBC per transfusion was not immunogenic on its own (J.W.S., unpublished data). Cell viability was measured as 80% to 95% by trypan blue dye exclusion. Incubation of the adherent APC with either syngeneic or allogeic platelets for 18 hours caused only a slight increase in the percentage of CD45^+CD61^+ cells (Table 1). Where indicated, IFN-γ (100 U/mL final) or the chemical inhibitors (0.5 or 1.0 mM AMG; 1 µg/mL colchicine; 0.1 mM chloroquine, 50 mM NH4 Cl, 1 µg/mL Brefeldin A, or 5 µM MG115, Table 2) were added to the platelet-pulsing step.

**Chloroquine pretreatment of platelets and APC**

Where indicated, platelets and APC were pretreated with chloroquine. Briefly, 10^9 platelets/mL were prepared in phosphate-buffered saline (PBS) containing 0.1 mM chloroquine and 0.4% bovine serum albumin (BSA) and incubated for 2 hours in the dark at room temperature. The platelets were then washed twice in PBS (containing 1% EDTA) and readjusted to 10^7/mL in cRPMI medium. For chloroquine pretreatment of APC, the adherent APC were incubated with the chloroquine solution on the Petri dishes and then washed as above.

**Transfusion protocol and blood preparation**

In each transfusion protocol, all mice were prebled 48 hours before the first transfusion and injected with 100 µL of the platelet-pulsed APC solution (10^7/mL) weekly via the tail vein. Each week, blood was collected from the mice into red top microvets (Sarstedt, Montreal, Quebec, Canada) and immediately placed on ice until clot formation. A portion of the fresh sera was used to determine antibody titers and the remainder was frozen at –80°C and used for cytokine determinations.

**Flow cytometric analysis**

For detection of IgG antidonor antibodies, 10^6 donor spleen cells were incubated with serial dilutions of fresh recipient sera for 45 minutes at 4°C, washed once, and labeled with FITC-conjugated goat antimouse IgG (Fc specific, Cedarlane Laboratories) for 45 minutes at 4°C in the dark. Cells were analyzed by flow cytometry using a FACSort flow cytometer (Becton Dickinson, San Jose, CA) equipped with an argon ion laser, operating at 15 mW.
mW; 10,000 events were acquired using an electronic cellular (lymphocyte) gate based on forward and side scatter and were analyzed using LYSYS II software (Becton Dickinson). Matched prebleed serum was used as the negative control in all experiments. Antidonor MHC specificity of the antibodies was confirmed by positive reactivity with donor cells but absence of reactivity with recipient or third-party cells. Isotype characterization of the antidonor antibodies was performed using FITC-conjugated goat antimouse IgG1 and 2a (Cedarlane Laboratories). For phenotypic analysis of adherent APC, scraped cells were stained with the indicated FITC-labeled or PE-labeled antibodies for 45 minutes in the dark, washed, and analyzed as above.

Cytokine determinations
Sera from the transfused mice or controls were tested for the presence of IL-4 and IL-12 using an ultrasensitive commercial solid-phase enzyme-linked immunosorbent assay (ELISA) kit (OptEIA Mouse IL-4 and IL-12 sets, PharMingen, San Diego, CA). The IL-4 kit had a sensitivity of more than 0.2 pg/mL and the IL-12 assay had a sensitivity of more than 5 pg/mL.

Statistical analysis
Chi square test for unpaired proportions was used to compare the number of antibody-positive recipients between 2 transfusion groups at each week of transfusion.

Results
Allogeneic platelet-pulsed APC immunity
To determine the immunogenicity of platelet-pulsed APC, 10⁶ were transfused weekly and the sera of the recipient mice were tested for the presence of antidonor IgG antibodies by flow cytometry. Control transfusions with syngeneic APC alone or syngeneic platelet-pulsed APC did not induce an antidonor IgG response in any mice tested (Figure 1A and B) nor did APC pulsed with the donor WBC amounts found in the allogeneic platelet population (not shown). In contrast, allogeneic platelet-pulsed APC induced detectable IgG antidonor antibody production by the second transfusion (Figure 1C); 45% of recipients had antidonor antibodies, and by the sixth transfusion 100% of recipients became antibody positive (Table 3). Thus, recipient APC became immunogenic when pulsed with donor platelets. Characterization of the serum IgG antibodies showed that they reacted strongly with donor MHC-matched cells (EL-4, H-2b) but not with recipient (P815, H-2d) or third-party (R1.1, H-2k) MHC cell lines. Isotype analysis of the IgG molecules showed that the pulsed APC induced the production of high-titer IgG1 (4990 ± 1213, mean ± SEM) and IgG2a (1933 ± 629) antidonor antibodies (Figure 2). In preliminary experiments, sera from immunized recipients could induce thrombocytopenia when infused into naive platelet donor mice;
Table 3. Percentage of mice with detectable antidonor alloantibody

<table>
<thead>
<tr>
<th>Agent Added to Pulse</th>
<th>Transfusion Week</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Pre 2 4 6</td>
</tr>
<tr>
<td>None</td>
<td>38 0 45 70 100 100</td>
</tr>
<tr>
<td>IFN-γ (100 U/mL)</td>
<td>10 0 80 (P &lt; .05)† 100 (P &lt; .05) 100 (n/s)</td>
</tr>
<tr>
<td>AMG (1 mM)</td>
<td>19 0 10 (P &lt; .01) 30 (P &lt; .05) 50 (P &lt; .0005)</td>
</tr>
<tr>
<td>Colchicine (1 µg/mL)</td>
<td>15 0 15 (P &lt; .05) 20 (P &lt; .01) 20 (P &lt; .0001)</td>
</tr>
<tr>
<td>NH₄Cl (50 mM)</td>
<td>10 0 40 (n/s) 80 (n/s) 100 (n/s)</td>
</tr>
<tr>
<td>Chloroquine (0.1 mM)</td>
<td>31 0 70 (P &lt; .05) 100 (P &lt; .01) 100 (n/s)</td>
</tr>
<tr>
<td>Brefeldin A (1 µg/mL)</td>
<td>9 0 100 (P &lt; .05) 100 (n/s) 100 (n/s)</td>
</tr>
<tr>
<td>MG115 (5 µM)</td>
<td>9 0 100 (P &lt; .05) 100 (n/s) 100 (n/s)</td>
</tr>
</tbody>
</table>

*APC were pulsed with donor platelets at a ratio of 10 platelets: 1 APC in the presence of the agents indicated, washed twice and 10⁶ APC were transfused weekly.

†Data are expressed as the percentage of recipients with detectable antidonor antibody by flow cytometry (rounded to nearest 5%).

The role of microtubules in platelet antigen processing

To determine the role of tubulin in platelet antigen processing, APC were pulsed with donor platelets in the presence of 1 µg/mL colchicine. Compared with nontreated pulsed APC, colchicine significantly inhibited the IgG antibody response; antidonor antibodies were detected in 15% of recipients by the second transfusion (P < .05, Table 3) and only 20% by the sixth transfusion (P < .0001, Table 3).

Recipient APC iNOS activation plays a critical role in platelet antigen processing

Previously we observed that when AMG was administered to recipient mice, it completely prevented formation of IgG antidonor antibodies against transfusions of intact platelets. To test the role of this inhibitor in affecting platelet antigen processing, recipient APC were pulsed with donor platelets in the presence of 1 mM AMG. Compared with AMG untreated-pulsed APC immunity, after 2 transfusions of AMG treated-pulsed APC, only 10% of recipients became antibody positive and 50% were antibody positive after 6 transfusions (P < .0005, Table 3). Flow cytometric analysis of recipient sera revealed that AMG significantly reduced the titers of total IgG, IgG1, IgG2a, alloantibodies (not shown).

Kinetic characteristics of the AMG effects on antibody production were studied by pulsing in the presence of either 0.5 mM AMG, 1 mM AMG, or 1 mM AMG plus 1 mM L-arg, the endogenous substrate for iNOS (Table 4). Both doses of AMG reduced the ability of pulsed APC to stimulate an IgG immune response. As expected, compared with the lower dose, 1 mM AMG caused an earlier inhibition because only 10% of the recipients were antibody positive after 2 transfusions (P < .02, Table 4). In contrast, co-incubation of AMG with an equimolar concentration (1 mM) of L-arg induced antibody production in all recipients by the second transfusion, that is, L-arg rescued and enhanced the AMG-mediated antibody inhibition (P < .05, Table 4). These results confirmed that modulation of iNOS activity within recipient APC significantly affects the alloantibody response.

Endosomal and nonendosomal pathways in APC differentially affect platelet antigen immunity

To distinguish between endosomal (pH dependent) and nonendosomal (pH independent) processing pathways, the lysosomotropic agents NH₄Cl and chloroquine were incubated with the platelet/APC cultures. Although the antibody response after NH₄Cl exposure was similar to responses seen with control transfusions (ie, without inhibitor), chloroquine significantly accelerated the IgG response in that 70% of recipients were antibody positive after the second transfusion (P < .05, Table 3) and all mice were positive by the fourth transfusion (P < .01, Table 3). Flow cytometric analysis of serum IgG revealed that chloroquine initially increased total IgG production, which subsequently declined (Figure 3). Concurrently, the chloroquine-treated pulsed APC markedly increased the production of IgG2a by the second transfusion (Figure 3), whereas the production IgG1 alloantibodies was inhibited throughout the entire transfusion protocol (Figure 3).

Table 4. Effects of in vitro AMG and L-arginine on the pulsed APC immunity

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N Pre 2 4 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>33 0 45 — 70 90 —</td>
</tr>
<tr>
<td>AMG (0.5 mM)</td>
<td>8 0 50 (n/s)‡ 25 (P &lt; .1) 50 (P &lt; .05)</td>
</tr>
<tr>
<td>AMG (1 mM)</td>
<td>19 0 10 (P &lt; .02) 30 (P &lt; .05) 50 (P &lt; .01)</td>
</tr>
<tr>
<td>AMG (1 mM) + L-Arg (1 mM)</td>
<td>8 0 100 (P &lt; .05) 100 (n/s)</td>
</tr>
</tbody>
</table>

*APC were pulsed with donor platelets at a ratio of 10 platelets: 1 APC in the presence of the agents indicated, washed twice and 10⁶ APC were transfused weekly.

†Data are expressed as the percentage of recipients with detectable antidonor antibody by flow cytometry (rounded to nearest 5%).

‡The x² test of independent proportions was used to compare the agent-treated pulsed APC groups against the nontreated pulsed APC group (n/s indicates not significant).
Thus, endosomal or chloroquine-sensitive (pH dependent) processing pathways of platelet antigens favor the production of IgG1 (Figure 2), whereas chloroquine-insensitive (pH independent) pathways are associated with elevated IgG2a responses (Figure 3). Because chloroquine can strip B₂M from the surface of platelets,27,28 we wanted to ensure that the chloroquine treatments were only affecting the adherent APC function. Donor platelets or APC were first pretreated with the 0.1-mM chloroquine dose in the pulsing step. Compared with nontreated platelets, pretreatment of platelets with 0.1 mM chloroquine did not affect the ability of the platelet-pulsed APC to induce IgG antibodies (Table 5). On the other hand, pretreatment of APC with 0.1 mM chloroquine before platelet pulsing enhanced its ability to stimulate IgG antibodies similarly to when chloroquine was added concurrently with the platelets; all recipients became antibody positive after the second transfusion (Table 5). Thus, the 0.1 mM dose of chloroquine in the APC pulsing cultures primarily affected APC function.

The role of cytosolic pathways in donor platelet antigen processing

To determine if the donor platelet antigens could be processed within the cytosolic compartment, the APC were pulsed with donor platelets in the presence of the proteasome inhibitory peptide MG115. In a similar fashion to chloroquine, MG115 significantly accelerated the IgG response so that 100% of recipients were antibody positive after the second transfusion ($P < .05$, Table 3), whereas it increased IgG2a titers during the entire transfusion protocol and decreased titers of IgG1 (Figure 3). Pulsing the APC in the presence of Brefeldin A caused similar results (Table 3 and Figure 3). Thus, inhibiting cytosolic pathways (proteasomes and nascent protein synthesis) increased the pulsed APC immunity and affected its ability to stimulate T-helper 1–associated and T-helper 2–associated IgG isotypes.

Inhibitor-mediated IgG2a production is associated with changes in serum IL-4 levels

Because murine IgG1 and IgG2a isotypes are associated with T-helper 1 and T-helper 2 cytokine patterns, respectively, serum IL-4 and IL-12 levels were analyzed by ELISA. None of the platelet-pulsed APC populations significantly affected IL-12 levels within the recipients (not shown). On the other hand, platelet-pulsed APC stimulated an initial rise in IL-4 sera levels at 1 and 2 weeks of transfusion, which subsequently declined to nontransfused serum levels by the sixth transfusion (Figure 4). However, when chloroquine, Brefeldin A, or MG115 was added to the APC/platelet cultures, a decrease in serum IL-4 levels was detected by the first and second transfusion (Figure 4).

Discussion

The recipient immune mechanisms that result in platelet alloimmunization remain relatively poorly understood. Our results suggest that platelet alloimmunization is fundamentally related to the antigen-processing and presentation mechanisms within recipient...
and AMG. This suggested that iNOS may be associated with a transient and early stimulation of splenic macrophage-mediated platelet transfusions stimulate alloantibody formation together with body production. We previously showed that allogeneic leukoreduced APC, which stimulate recipient T-helper cells and eventual alloantibody production. We previously showed that allogeneic leukoreduced platelet transfusions stimulate alloantibody formation together with a transient and early stimulation of splenic macrophage-mediated cytotoxicity.23 Both responses could be completely suppressed in vivo by inhibitors of iNOS such as N\textsuperscript{\textomega}-monomethyl-L-arginine\textsuperscript{23} and AMG.24 This suggested that iNOS may be associated with platelet antigen-processing mechanism(s) within the APC, which was responsible for platelet immunity. To study the processing pathways in recipient APC, we used an in vitro system in which adherent APC from recipient mice were pulsed with allogeneic platelets and then transfused weekly into naive recipient mice. Our results show that recipient APC pulsed with donor platelets produced high-titer IgG antidonor MHC class I antibodies when transfused, and that iNOS activation was an essential APC processing event leading to alloantibody formation. In addition, both endosomal and nonendosomal processing compartments within the APC were used to process platelet antigens, and these pathways affected the isotype profile of the alloantibody response.

The IgG antibody response induced by the platelet-pulsed APC was specific for intact MHC class I molecules on donor leukocytes. The only source of intact allogeneic MHC class I within the washed pulsed APC that could prime antigen-reactive B cells for T-cell help would be those present on free donor platelets. We estimated that less than 5 \times 10^6 free platelets (including both donor-derived and recipient-derived platelets) from the pulsing step were actually transfused. Although these numbers are too low to induce an antibody response themselves,\textsuperscript{26} they could be in sufficient quantity to prime antigen-specific B cells to become reactive to the T-cell help generated by the pulsing APC. Furthermore, small numbers of donor WBC from the pulsing step may have been potentially transfused. We estimated that up to approximately 10 donor WBC could potentially have been transfused, but in control experiments these numbers of donor WBC could not stimulate immunity on their own. Thus, the observed immunity generated was primarily due to the recipient APC pulsed with donor platelets. The ability of the donor platelet pulsing step to induce antibody (ie, the immunostimulatory platelet antigen-processing pathway) was sensitive to AMG, a selective inhibitor of iNOS,\textsuperscript{29,30} and colchicine, an inhibitor of tubulin formation.31 The colchicine sensitivity suggests that platelets require tubulin-dependent processes (eg, phagocytosis), possibly to be taken up and transported to phagolysosomes for destruction. With respect to AMG, our previous results showed that when AMG was administered to recipient mice, it completely inhibited their ability to mount an IgG alloantibody response against intact donor platelet transfusions.25 Our current results are consistent with this in that AMG significantly inhibited the ability of APC to stimulate alloantibody production (Table 3). Thus, it appears that iNOS activation is an essential platelet-processing step within APC responsible for IgG alloantibody production. However, how iNOS and its product nitric oxide (NO) actually mediate platelet antigen processing is unknown, but 2 possibilities exist. Because iNOS is known to associate with phagolysosome membranes,\textsuperscript{32,33} perhaps NO itself, or its conversion to peroxynitrite (ONOO\textsuperscript{−}) in the presence of superoxide, directly causes platelet membrane glycoprotein damage (eg, due to nitration, unfolding, or cleavage) to generate MHC class II-binding motifs within the phagolysosomes. Because endosomes containing MHC class II molecules normally fuse with phagolysosomes,\textsuperscript{34} it may allow for the NO-processed platelet antigens to be loaded into the antigen-binding grooves of the MHC molecules for subsequent transport to the surface. Alternatively, NO significantly affects F-actin rearrangements and intracellular membrane movements, which could physically shunt platelet antigens to sites rich in MHC molecules.\textsuperscript{35,36} It is possible that a combination of both mechanisms could affect platelet antigen processing and ultimately antibody production. We are currently studying these possibilities. The current results support the concept that manipulating NO levels within recipient APC may be an effective and selective immunotherapy for the total reduction of alloimmunization against leukoreduced platelets.

Classically, for MHC class II presentation and subsequent stimulation of antibody production, exogenous protein antigens need to be shunted to endosomal compartments within the APC for processing by pH-dependent (eg, sensitive to the lysosomotropic agents, chloroquine and NH\textsubscript{4}Cl) proteases such as the cathepsins.3,5 The experiments using lysosomotropic agents, particularly chloroquine, showed that it actually enhanced the recipients' ability to produce IgG more quickly against the platelet-pulsed APC (Table 3). This suggests that processing of exogenously added donor platelet antigens can occur via a chloroquine insensitive or nonendosomal cellular pathway. Paradoxically, we found that chloroquine treatment of the recipient APC reduced their ability to stimulate non-complement-fixing IgG1 and transiently, but significantly, enhanced the production of complement-fixing IgG2a antibodies (Figure 3). Thus, both endosomal and nonendosomal processing pathways can act on platelet antigens; endosomal (chloroquine-sensitive) processing may be responsible for IgG1 alloantibody responses, whereas both endosomal and particularly nonendosomal (chloroquine insensitive) pathways regulate IgG2a production. These data are one of the few examples in which an exogenous protein antigen can be handled by an APC for subsequent MHC class II-dependent antibody production without the requirement for endosomal (chloroquine-independent) processing; to our knowledge, this has only been shown to occur for influenza matrix protein\textsuperscript{13} and measles virus protein.14 Several laboratories have confirmed that T-cell responses to exogenous antigen can be chloroquine insensitive if the protein antigens have been previously degraded into peptide fragments.3,37 For example, chemically
modified myoglobin, denatured lysozyme, and the unfolded carboxy-terminal epitope of fibrinogen all can be presented to MHC class II-restricted T-cell clones, even in the presence of enough chloroquine to completely block the presentation of the native protein. Because chloroquine can potentially modify MHC by stripping β2M, we ensured it was not directly acting on the platelets in the pulsing step by showing that pretreating the platelets with 0.1 mM chloroquine did not affect the platelets' ability to convert adherent APC into immunogenic cells (Table 5). The significance of chloroquine-insensitive (nonendosomal) processing of platelet antigens is not yet known, but because IgG1 and IgG2a isotypes are closely associated with T-helper 2 and T-helper 1 activation, respectively, it may suggest that the different processing pathways (endosomal versus nonendosomal) affect the isotype patterns via differential T-cell activation. In support of this, chloroquine-treated APC significantly reduced the serum levels of IL-4 in the recipient mice by the second transfusion (Figure 4).

Furthermore, the results (Figure 3) showing that Brefeldin A also enhanced IgG2a production while suppressing IgG1 antibodies additionally suggests that nascent protein synthesis (eg, MHC class II) within the APC may be required for IgG1 but not IgG2a production. Perhaps IgG2a production uses recycled MHC class II molecules from the APC surface, as has been shown to occur for other protein antigens. Taken together, our data suggest the intriguing possibility that different processing pathways may shunt platelet antigens to different intracellular compartments or MHC class II molecules, which can induce differential stimulation of IgG isotypes.

It is generally thought that exogenous antigens do not enter the cytosolic (proteasome) pathway of antigen processing that is mainly responsible for the generation of MHC class I peptide complexes for recognition by CTL. We previously reported that allogeneic platelet transfusions are associated with the generation of CD8+ CTL and immune nonresponsiveness in C57BL/6 recipients is reversed when CD8+ T cells are deleted (eg, CD8 knockout mice). However, the proteasome inhibitory peptide MG115 actually enhanced the ability of pulsed APC to stimulate IgG2a production and argues that if CD8+ T cells are being activated by the MHC class I processing pathway, they do not appear to inhibit the immune response (eg, by activated CTL lysing recipient APC as they are presenting platelet antigens). The fact that MG115 elevated IgG2a production indicates that exogenous platelet antigens can reach the cytosolic MHC class I pathway, and its inhibition may make more antigen available for the MHC class I pathways.

In summary, allogeneic platelet antigens have unique antigen-processing requirements to stimulate antidonor MHC class I antibody formation. Within the recipient APC, platelet-derived MHC class I molecules need exposure to iNOS activation and can use either an endosomal or nonendosomal processing pathway to generate immunogenic motifs that control the stimulation of IgG alloantibody formation. Our results may have application for those clinical situations where platelet recipients become alloimmunized despite receiving leukoreduced platelets or potential application in those already immunized recipients (eg, due to prior pregnancy or transfusion) who receive leukoreduced platelet products. Overall, our results suggest that platelet processing pathways, particularly related to iNOS, may be targets for the development of specific immunotherapies to prevent alloimmunization in these patients.

Acknowledgment

The authors would like to thank Dr Jung H. Oh (Department of Experimental Pathology, Emory University, Atlanta, GA) for his helpful discussions and encouragement.

References

of the IX International Congress of Immunology.


